Skip to main content

Table 4 Pharmacoeconomic impact (topic 4)

From: Unmet needs about iron deficiency in peritoneal dialysis: a Delphi consensus panel

Statement 16

Referring to the use of I.V. iron and to the costs optimization for the treatment of anaemia in the patient in peritoneal dialysis, I retain:

1

2

3

4

5

 16.1 That an evaluation should be performed

8%

92%

 

2

0

5

13

5

 16.2 That the use of ferric carboxymaltose let a reduction of the use of ESA which is able to overrule the greater cost of the drug itself

8%

92%

 

0

2

3

9

11

 16.3 To observe an improvement in clinical outcomes but not in the use of ESA

32%

68%

 

1

7

10

5

2

 16.4 That the hospital pharmacy does not consent the use of iron molecules at a higher cost

68%

32%

 

5

12

4

4

0

 16.5 That pharmacoeconomic data now available do not let to clearly highlight an advantage among different molecules

52%

48%

 

4

9

7

3

2